Skip to content

Depression: all studies

Page 381 of 1,040: studies 3,801 to 3,810 of 10,391, newest first. Back to the depression overview

Research

Perinatal Understanding of Mindful Awareness for Sleep (PUMAS): A single-arm proof-of-concept clinical trial of a mindfulness-based intervention for DSM-5 insomnia disorder during pregnancy.

Sleep Medicine August 1, 2023 David A Kalmbach, Philip Cheng, Anthony N Reffi et al. 15 citations

Cognitive-behavioral therapy is effective for prenatal insomnia, but unresolved cognitive arousal limits patient outcomes. Therapies aimed at reducing cognitive arousal may benefit pregnant women with insomnia. This proof-of-concept trial evaluated Perinatal Understanding of Mindful Awareness for Sleep (PUMAS, which combines mindfulness with behavioral sleep strategies) on insomnia, depression,...

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.

Journal of Affective Disorders August 1, 2023 Richard J. Zeifman, Anne C Wagner, Candice M Monson et al. 56 citations

Psilocybin therapy is receiving attention as a mental health intervention with transdiagnostic potential. In line with psychotherapeutic research, qualitative research has highlighted the role of reductions in experiential avoidance (and increases in connectedness) within psilocybin therapy. However, no quantitative research has examined experiential avoidance as a mechanism underlying...

A pilot evaluation of an 8-week mindfulness-based stress reduction program for people with pre-symptomatic Huntington's disease.

Journal of community genetics July 17, 2023 Sarah Velissaris, Marie‐Claire Davis, Fiona Fisher et al.

People with Huntington's disease (HD) face difficult emotional and practical challenges throughout their illness, including in the pre-symptomatic stage. There are, however, extremely limited psychosocial interventions adapted to or researched for HD. We adapted and piloted an 8-week mindfulness-based stress reduction (MBSR) program in people with pre-symptomatic HD to determine if the program...

The current state of ayahuasca research in animal models: A systematic review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 13, 2023 Dimitri Daldegan-Bueno, Natalia Maria Simionato, Vanessa Manchim Favaro et al. 18 citations

The psychedelic brew ayahuasca is increasingly being investigated for its therapeutic potential. Animal models are essential to investigate the pharmacological effects of ayahuasca since they can control important factors influencing it, such as the set and setting. Review and summarise data available on ayahuasca research using animal models. We systematically searched five databases (PubMed,...

[Psychedelic Experiences: Phenomenology, Therapeutic Potentials and Explanatory Models].

Vertex Revista Argentina de Psiquiatría July 10, 2023 Tamara Chernoff, Bruno Kliger, Dante Hernán Venturini

Traditional psychedelics, such as LSD, psilocybin, or DMT, are psychoactive compounds that exert their effects mainly through agonism over serotonergic receptors. In appropriate doses and contexts, they produce profound changes in the subjective experience, configuring altered states of consciousness that, upon reaching a critical point, involve the appearance of phenomena of mystical,...

The Mediating Role of Precepts and Meditation on Attachment and Depressive Symptoms in Adolescents.

Healthcare July 3, 2023 Justin DeMaranville, Tinakon Wongpakaran, Nahathai Wongpakaran et al. 6 citations

Research shows that Buddhist precept adherence (i.e., abstaining from killing, stealing, sexual misconduct, lying, and intoxicant use) and meditation practice influence mental health outcomes. This study investigated how Buddhist precept adherence and meditation practice influenced the relationship between insecure attachment and depressive symptoms among Thai adolescents. A total of 453 Thai...

Daily Δ9-Tetrahydrocannabinol and Withdrawal Increase Dopamine D1-D2 Receptor Heteromer to Mediate Anhedonia- and Anxiogenic-like Behavior Through a Dynorphin and Kappa Opioid Receptor Mechanism.

Biological Psychiatry Global Open Science July 2023 Ahmed Hasbi, Bertha K. Madras, Susan R George

Frequent cannabis use is associated with a higher risk of developing cannabis use disorder and other adverse consequences. However, rodent models studying the underlying mechanisms of the reinforcing and withdrawal effects of the primary constituent of cannabis, Δ9-tetrahydrocannabinol (THC), have been limited. This study investigated the effects of daily THC (1 mg/kg, intraperitoneal, 9 days)...

Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity

The World Journal of Biological Psychiatry June 20, 2023 Maria Gałuszko‐węgielnik, Katarzyna Jakuszkowiak‐wojten, Alina Wilkowska et al. 9 citations

OBJECTIVES: Borderline personality disorder (BPD) and bipolar disorder (BD) often co-occur and frequently do not respond adequately to traditional antidepressant treatments. Ketamine has shown rapid antidepressant and anti-suicidal effects. However, there is limited literature on the safety and tolerance of using ketamine to treat patients with comorbid BD and BPD. METHODS: This case presents a...

Mantram repetition and psychological distress: A systematic review and meta-analysis.

Journal of Psychiatric and Mental Health Nursing June 2023 Joanne Kraenzle Schneider, Saratu Garba Abdullahi, Scott D Easton et al.

WHAT IS KNOWN ON THE SUBJECT?: Researchers have examined several interventions for psychological distress, mindfulness being a popular one. One intervention that fosters mindfulness is mantram repetition. Mantram repetition is an ancient traditional practice of repeating a sacred word/phrase at various times throughout the day and whenever needed. Psychologically, mantram repetition can...

Pharmacotherapy: Ketamine and Esketamine.

Psychiatric Clinics of North America June 2023 Anna Feeney, George I. Papakostas

Ketamine and esketamine have rapid-onset antidepressant effects and may be considered for the management of treatment-resistant depression. Intranasal esketamine has regulatory approval in the United States and European Union. Intravenous ketamine is often administered off-label as an antidepressant, though no standard operating procedures exist. Repeated administrations and the use of a...